EFEITO DO ETORICOXIBE NO CONTROLE DA DOR EM DISFUNÇÕES TEMPOROMANDIBULARES: UM ENSAIO CLÍNICO RANDOMIZADO

• Ano de defesa: 2023
• Autor(a) principal: Mortari, Tiago Lauermann
• Orientador(a): Skupien, Jovito Adiel
• Banca de defesa: Weber , Alexandre, Blaya , Diego Segatto
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Franciscana
• Programa de Pós-Graduação: Mestrado em Ciências da Saúde e da Vida
• Departamento: Ciências da Saúde e da Vida
• País: Brasil
• Palavras-chave em Português: Anti-inflamatórios; Ensaio Clinico Controlado Aleatório; Qualidade de vida; Síndrome da disfunção da Articulação temporomandibular.
• Palavras-chave em Inglês: Anti-inflammatories; Random Controlled Clinical Trial; Quality of life; Temporomandibular joint dysfunction syndrome.
• Área do conhecimento CNPq: Ciências da Saúde e da Vida
• Link de acesso: http://www.tede.universidadefranciscana.edu.br:8080/handle/UFN-BDTD/1204

Orofacial pain and temporomandibular disorders (TMD) are conditions that result in severe pain and limitations of mandibular movement, requiring control through treatments ranging from less invasive to surgical, seeking to reestablish function and improve the quality of life of individuals. Thus, the aim of this study was to evaluate the impact of using etoricoxib on pain, mouth opening and oral health-related quality of life (OHRQoL) in patients with orofacial pain and TMD. A randomized, double-blind clinical trial (patient and evaluator), with two groups in parallel, was carried out, where etoricoxib 45mg was administered orally to the test group and placebo to the control group, both twice a day, for 7 days. Furthermore, cyclobenzaprine hydrochloride 10mg orally was administered before bedtime for 14 days to all patients. Thirty-four patients were evaluated (test=19 and placebo=15). Both groups showed better mouth opening, lower pain intensity and improvement in OHRQoL after the use of cyclobenzaprine, however, the use of etoricoxib did not have a statistically significant influence on any of the outcomes. Cyclobenzaprine alone was able to improve signs and symptoms related to TMD. Other studies using etoricoxib with different dosages and without administration of another previous drug should be carried out.